|
1
|
Meijer CJ and Berkhof J: Screening:
Cervical cancer - should we abandon cytology for screening? Nat Rev
Clin Oncol. 9:558–559. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li J, Kang LN and Qiao YL: Review of the
cervical cancer disease burden in mainland China. Asian Pac J
Cancer Prev. 12:1149–1153. 2011.PubMed/NCBI
|
|
3
|
Shi JF, Canfell K, Lew JB and Qiao YL: The
burden of cervical cancer in China: synthesis of the evidence. Int
J Cancer. 130:641–652. 2012. View Article : Google Scholar
|
|
4
|
Hung CF, Wu TC, Monie A and Roden R:
Antigen-specific immunotherapy of cervical and ovarian cancer.
Immunol Rev. 222:43–69. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ameres SL and Zamore PD: Diversifying
microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun K and Lai EC: Adult-specific functions
of animal microRNAs. Nat Rev Genet. 14:535–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Haflidadóttir BS, Larne O, Martin M, et
al: Upregulation of miR-96 enhances cellular proliferation of
prostate cancer cells through FOXO1. PLoS One. 8:e724002013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu L, Li H, Jia CY, et al: MicroRNA-223
regulates FOXO1 expression and cell proliferation. FEBS Lett.
586:1038–1043. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu Z, Sun H, Zeng W, He J and Mao X:
Upregulation of MircoRNA-370 induces proliferation in human
prostate cancer cells by downregulating the transcription factor
FOXO1. PLoS One. 7:e458252012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mai CW, Kang YB and Pichika MR: Should a
Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to
treat cancer? TLR-4: its expression and effects in the ten most
common cancers. Onco Targets Ther. 6:1573–1587. 2013.PubMed/NCBI
|
|
11
|
Deivendran S, Marzook KH and Radhakrishna
Pillai M: The role of inflammation in cervical cancer. Adv Exp Med
Biol. 816:377–399. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ding G, Liu HD, Huang Q, et al: HDAC6
promotes hepatocellular carcinoma progression by inhibiting P53
transcriptional activity. FEBS Lett. 587:880–886. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Grönroos E, Terentiev AA, Punga T and
Ericsson J: YY1 inhibits the activation of the p53 tumor suppressor
in response to genotoxic stress. Proc Natl Acad Sci USA.
101:12165–12170. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liao WR, Hsieh RH, Hsu KW, et al: The
CBF1-independent Notch1 signal pathway activates human C-myc
expression partially via transcription factor YY1. Carcinogenesis.
28:1867–1876. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao S, Yao D, Chen J and Ding N:
Circulating miRNA-20a and miRNA-203 for screening lymph node
metastasis in early stage cervical cancer. Genet Test Mol
Biomarkers. 17:631–636. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
How C, Hui AB, Alajez NM, et al:
MicroRNA-196b regulates the homeobox B7-vascular endothelial growth
factor axis in cervical cancer. PLoS One. 8:e678462013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu X, Er K, Mao C, et al: miR-203
suppresses tumor growth and angiogenesis by targeting VEGFA in
cervical cancer. Cell Physiol Biochem. 32:64–73. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi L, Cheng Z, Zhang J, et al:
hsa-mir-181a and hsa-mir-181b function as tumor suppressors in
human glioma cells. Brain Res. 1236:185–193. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang B, Hsu SH, Majumder S, et al:
TGFbeta-mediated upregulation of hepatic miR-181b promotes
hepatocarcinogenesis by targeting TIMP3. Oncogene. 29:1787–1797.
2010. View Article : Google Scholar :
|
|
20
|
Donohoe ME, Zhang X, McGinnis L, et al:
Targeted disruption of mouse Yin Yang 1 transcription factor
results in peri-implantation lethality. Mol Cell Biol.
19:7237–7244. 1999.PubMed/NCBI
|
|
21
|
Lu Y, Xiong X, Wang X, et al: Yin Yang 1
promotes hepatic gluconeogenesis through upregulation of
glucocorticoid receptor. Diabetes. 62:1064–1073. 2013. View Article : Google Scholar :
|
|
22
|
Wang H, Garzon R, Sun H, et al:
NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis
and rhabdomyosarcoma. Cancer Cell. 14:369–381. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gordon S, Akopyan G, Garban H and Bonavida
B: Transcription factor YY1: structure, function, and therapeutic
implications in cancer biology. Oncogene. 25:1125–1142. 2006.
View Article : Google Scholar
|
